# Pertuzumab

## Perjeta inj 420mg/14mL

##### 臨採

| 藥品代碼   | IPERJ                                                                                                                                                                                                                                                                                                                                                           |
|:-----------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 適應症     | PERJETA? (pertuzumab) is approved for use in combination with Herceptin? (trastuzumab) and docetaxel (chemotherapy) in people who have HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer.                                        |
| 用法用量   | Initial dose of 840 mg infused over 60 minutes followed by a maintenance dose of 420 mg infused over 30-60 minutes every 3 weeks.                                                                                                                                                                                                                               |
| 肝功能異常 | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                    |
| 腎功能異常 | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                    |
| 禁忌       | Treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer.                                                                                                                                                                                                                                                                 |
| 副作用     | The most common side effects of PERJETA when given with Herceptin and docetaxel (chemotherapy) for treatment of breast cancer that has spread to other parts of the body (metastatic) are: Diarrhea Hair loss Low levels of white blood cells with or without a fever Nausea Feeling tired Rash Damage to the nerves (numbness， tingling， pain in hands/feet) |
| 孕期建議   | No Data                                                                                                                                                                                                                                                                                                                                                         |
| 哺乳期建議 | Human Data Suggest Potential Toxicity                                                                                                                                                                                                                                                                                                                           |

